Celgene International Sárl (CELG) Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
5/23/2013 11:08:54 AM
More...
|
Celgene International Sárl (CELG) Release: Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials
1/7/2013 10:24:21 AM
More...
|
Celgene International Sárl (CELG) Release: Data Evaluating Combination Treatments Including REVLIMID® Plus Antibody Therapies in Patients With Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American Society of Hematology Annual Meeting
12/12/2012 9:30:25 AM
More...
|
Celgene International Sárl (CELG) Release: Results of Pivotal Study (MCL-001) Evaluating REVLIMID in Mantle-Cell Lymphoma Presented at 54th American Society of Hematology Annual Meeting
12/11/2012 10:21:46 AM
More...
|
Celgene International Sárl (CELG) Release: Analysis of Post-Progression Outcomes in MM-015 Study Presented at the 54th American Society of Hematology Annual Meeting
12/11/2012 10:01:54 AM
More...
|
Celgene International Sárl (CELG) Release: Study to Evaluate Dose and Schedule for Oral Epigenetic Therapy CC-486 in Lower-Risk MDS Presented at American Society of Hematology
12/10/2012 10:17:44 AM
More...
|
Celgene International Sárl (CELG) Release: Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase 3 Study (Palace-1) in Patients With Psoriatic Arthritis
11/13/2012 2:24:54 PM
More...
|
Celgene International Sárl (CELG) Release: ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
10/25/2012 10:03:41 AM
More...
|
Celgene International Sárl (CELG) Myeloma Treatment Meets Phase 3 Goals
10/23/2012 7:26:48 AM
More...
|
Celgene International Sárl (CELG) Release: Apremilast Palace Program Demonstrates Robust and Consistent Statistically Significant Clinical Benefit Across Three Pivotal Phase III Studies (PALACE-1, 2 & 3) in Psoriatic Arthritis
9/6/2012 10:16:49 AM
More...
|
|